The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
The effectiveness of minoxidil in patients with resistant hypertension is well established. In one report, 11 patients with hypertension given minoxidil alone saw their mean BP fall from 188/124 ...